Treatment 8 min
GIST (gastrointestinal stromal tumour): treatment with imatinib and what to do when it stops working
GIST: the role of KIT and PDGFRA mutations, assessing recurrence risk, surgery, adjuvant imatinib for three years, lines of therapy in advanced disease, side effects and follow-up.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 31 October 2026
GIST (gastrointestinal stromal tumour) is the most common sarcoma of the digestive tract. This disease used to be considered practically insensitive to treatment until imatinib appeared: a drug that blocks the protein that makes the tumour grow. It is one of the first success stories of targeted therapy.
In this article I explain what GIST is, why mutation testing is needed, how recurrence risk is assessed, who needs imatinib after surgery, which drugs are used in advanced disease and how to cope with side effects. How targeted treatment works in general: targeted therapy.
What GIST is
GIST develops from special cells in the wall of the gastrointestinal tract (cells of Cajal). It is most often located in the stomach (around half of cases or more) and small bowel, less often in the esophagus, colon and rectum. Many GISTs are caused by mutations in the KIT or PDGFRA genes, because of which the protein is permanently "switched on" and signals the cell to grow.
GIST is unlike stomach or bowel cancer: the chemotherapy used for those tumours hardly affects it. So the diagnosis must be confirmed properly: the report should include stains for CD117 (KIT) and DOG1.
What to do before treatment starts
- CT or MRI of the abdomen and pelvis: size, location, relation to organs, distant lesions (CT with contrast);
- pathology with immunohistochemistry (CD117, DOG1);
- mitotic count (the number of dividing cells in a given area): one of the main indicators of risk;
- KIT and PDGFRA mutation testing (and if needed other genes, for example SDH or NF1). It is best done before imatinib is started, because the result determines the choice of drug and dose (NGS);
- if metastases are suspected, PET-CT (what PET-CT shows).
GIST biopsy is done with caution because the tumour can bleed or rupture. It is planned by an experienced team, and in some cases when surgery is clearly indicated the diagnosis is confirmed after it.
How recurrence risk is assessed
The risk of recurrence after surgery depends on four factors:
| Factor | What it means |
|---|---|
| Tumour size | The larger, the higher the risk |
| Mitotic count | The more dividing cells, the higher the risk |
| Location | In the stomach risk is usually lower, in the small bowel and rectum higher |
| Tumour rupture | Rupture before or during surgery sharply raises the risk |
Taken together, the tumour is assigned to a very low, low, intermediate or high risk group. Whether imatinib is needed after surgery depends on it. It is important that these data are in the report: if the mitotic count or size is missing, risk cannot be assessed.
Surgery
The main treatment of localised GIST is complete removal of the tumour without damaging its capsule (R0), usually without removing lymph nodes because GIST rarely spreads through lymph. Small stomach tumours are sometimes removed laparoscopically. The main rule is to avoid tumour rupture, because it sharply raises the risk.
If complete removal would require a very disruptive operation (for example removing the whole stomach or rectum), preoperative imatinib is discussed: it shrinks the tumour so that the operation is less extensive. The decision depends on the mutation: with some variants imatinib does not work, so testing is needed in advance.
Imatinib after surgery
At high risk of recurrence the standard is imatinib 400 mg a day for three years. Trials showed that three years gives better recurrence-free and overall survival than one year. For selected patients at very high risk longer treatment is discussed, but the decision is individual and made by the doctor after assessing tolerability.
Imatinib is not given if the tumour has a mutation for which it is poorly effective (for example PDGFRA D842V or SDH-deficient GIST). This is another reason to check the mutations before taking the drug for years.
Advanced and metastatic GIST
When the disease has spread or returned, the basis of treatment is targeted drugs taken long-term.
| Line | Drug | Note |
|---|---|---|
| First | Imatinib 400 mg, and 800 mg often in KIT exon 9 mutation | The mutation determines the dose |
| Second | Sunitinib | After progression or intolerance of imatinib |
| Third | Regorafenib | |
| Fourth | Ripretinib | Where registered |
| PDGFRA D842V mutation | Avapritinib | Imatinib is poorly effective |
For GIST without KIT and PDGFRA mutations (including SDH-deficient and with other mutations) regimens differ, and such a case should definitely be discussed at an experienced centre. Response is assessed by CT or MRI (sometimes PET-CT) every 3 months at the start and less often later (RECIST, metabolic response). If treatment stops working, it is important to confirm progression and discuss the next step: progression on treatment, clinical trials.
Sometimes with limited progression (a single lesion) surgery or local treatment of that lesion is discussed while the drug continues.
Side effects
Imatinib:
- oedema (especially around the eyes and on the legs) and fluid retention;
- nausea, diarrhoea, abdominal pain;
- muscle cramps and bone pain;
- rash (skin reactions on targeted therapy);
- fatigue, reduced blood counts;
- changes in liver enzymes.
The drug should be taken with food and a glass of water, and doses should not be skipped.
Sunitinib and regorafenib:
- raised blood pressure;
- hand-foot syndrome (hand-foot syndrome);
- diarrhoea, fatigue, inflammation of the mucosa;
- reduced thyroid function (with sunitinib).
Drug interactions. Imatinib and other targeted drugs interact with a number of medicines and supplements (grapefruit, St John's wort and others) that can change its level. Discuss any supplements and herbs with your doctor beforehand: alcohol, supplements and herbs during treatment.
Many side effects are manageable with early contact. If you are unsure how serious a symptom is: when to call your doctor.
Follow-up
After surgery, examinations and CT or MRI are more frequent in the first years (usually every 3–6 months) and less frequent later, for 5 years or more depending on risk. The higher the risk, the more often the check. Recurrences in high-risk GIST are possible even after imatinib has ended, so follow-up remains important.
What to ask your doctor
- What is my recurrence risk (size, mitoses, location, rupture)?
- Which mutation was found? Was testing done before treatment?
- Is imatinib needed after surgery and for how many years?
- Which imatinib dose suits me?
- How do we control side effects and when should I call?
- What do we do at progression?
- Can I take my other medicines and supplements?
When to seek urgent help
- black stool, vomiting blood, weakness and dizziness (possible bleeding);
- severe abdominal pain;
- rapid weight gain, swelling, shortness of breath;
- temperature of 38 °C or above;
- jaundice, dark urine;
- severe headache or blood pressure above 180/110.
Can I get a second opinion
Yes, and in GIST it often really changes tactics. Reasons: no mutation testing or risk assessment, chemotherapy is offered (it hardly works in GIST), extensive surgery is offered without discussing preoperative imatinib, progression on the drug or a question about treatment duration. Prepare the pathology, mutation results, CT or MRI and summaries: documents for a second opinion, preparing for a consultation. If you need a review, book a consultation: I study the documents in advance and send a written summary. General information about other sarcomas: soft tissue sarcoma, stomach and esophageal cancer.
Sources
- Gastrointestinal Stromal Tumors Treatment (PDQ) — National Cancer Institute
- ESMO Clinical Practice Guidelines — ESMO
- Practical guidelines for drug treatment of malignant tumours — RUSSCO (Russian Society of Clinical Oncology)
- Clinical guidelines (Russia) — Russian Ministry of Health
Frequently asked questions
This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.
